BLFS
Price
$38.26
Change
-$0.32 (-0.83%)
Updated
Sep 25, 11:57 AM (EDT)
Capitalization
1.85B
41 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$9.55
Change
+$0.02 (+0.21%)
Updated
Sep 25, 12:16 PM (EDT)
Capitalization
1.9B
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BLFS vs XRAY

BLFS vs XRAY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BLFS vs. XRAY commentary
Sep 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a Buy and XRAY is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BLFS vs XRAY: Fundamental Ratings
BLFS
XRAY
OUTLOOK RATING
1..100
3273
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5697
PRICE GROWTH RATING
1..100
3663
P/E GROWTH RATING
1..100
3282
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (3) in the Medical Specialties industry is significantly better than the same rating for BLFS (98). This means that XRAY’s stock grew significantly faster than BLFS’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BLFS (100). This means that XRAY’s stock grew similarly to BLFS’s over the last 12 months.

BLFS's SMR Rating (56) in the Medical Specialties industry is somewhat better than the same rating for XRAY (97). This means that BLFS’s stock grew somewhat faster than XRAY’s over the last 12 months.

BLFS's Price Growth Rating (36) in the Medical Specialties industry is in the same range as XRAY (63). This means that BLFS’s stock grew similarly to XRAY’s over the last 12 months.

BLFS's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for XRAY (82). This means that BLFS’s stock grew somewhat faster than XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BLFSXRAY
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
60%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
54%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 23 days ago
57%
Declines
ODDS (%)
Bearish Trend 16 days ago
83%
Bearish Trend 1 day ago
73%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
60%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
73%
COMPARISON
Comparison
Sep 25, 2026
Stock price -- (BLFS: $38.58 vs. XRAY: $9.53)
Brand notoriety: BLFS and XRAY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BLFS: 93% vs. XRAY: 94%
Market capitalization -- BLFS: $1.85B vs. XRAY: $1.95B
BLFS [@Pharmaceuticals: Other] is valued at $1.85B. XRAY’s [@Pharmaceuticals: Other] market capitalization is $1.95B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $141.89B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $8.77B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BLFS’s FA Score shows that 1 FA rating(s) are green while XRAY’s FA Score has 1 green FA rating(s).

  • BLFS’s FA Score: 1 green, 4 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, BLFS is a better buy in the long-term than XRAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLFS’s TA Score shows that 3 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).

  • BLFS’s TA Score: 3 bullish, 5 bearish.
  • XRAY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XRAY is a better buy in the short-term than BLFS.

Price Growth

BLFS (@Pharmaceuticals: Other) experienced а +4.69% price change this week, while XRAY (@Pharmaceuticals: Other) price change was +1.65% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.82%. For the same industry, the average monthly price growth was -3.30%, and the average quarterly price growth was +19.99%.

Reported Earning Dates

BLFS is expected to report earnings on Nov 05, 2026.

XRAY is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (+1.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
BLFS
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BTRN27.450.09
+0.35%
Global X Bitcoin Trend Strategy ETF (BTRN)
GNOV42.86N/A
-0.01%
FT Vest U.S. Equity Moderate Buffer ETF - November (GNOV)
FNOV60.18-0.01
-0.02%
FT Vest U.S. Equity Buffer ETF - November (FNOV)
BCIL28.79-0.20
-0.69%
Bancreek International Large Cap ETF (BCIL)
RNRG32.33-0.59
-1.80%
Global X Renewable Energy Producers ETF (RNRG)

BLFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLFS
1D Price
Change %
BLFS100%
+2.23%
RGEN - BLFS
56%
Loosely correlated
+3.32%
RVTY - BLFS
51%
Loosely correlated
+6.03%
A - BLFS
50%
Loosely correlated
+4.55%
XRAY - BLFS
48%
Loosely correlated
-2.56%
DHR - BLFS
47%
Loosely correlated
+1.00%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
-2.56%
NVST - XRAY
62%
Loosely correlated
+1.05%
ALGN - XRAY
58%
Loosely correlated
-1.72%
QDEL - XRAY
50%
Loosely correlated
+3.38%
KIDS - XRAY
48%
Loosely correlated
+1.39%
STE - XRAY
46%
Loosely correlated
-0.58%
More